艾美疫苗(06660.HK)呼吸道合胞病毒疫苗向美国申报临床

阿斯达克财经
05 Feb

艾美疫苗(06660.HK) 公布,按照既定公司战略积极推进疫苗产品管线的开发,利用mRNA技术平台优势,通过持续的技术创新,快速推进mRNA疫苗系列产品的研发,mRNA RSV (呼吸道合胞病毒)疫苗已于近日向美国食品和药监局(FDA)申报临床。

临床前动物试验中,第三方检测单位的检测结果显示,集团mRNA RSV疫苗特异性IgG抗体滴度、真病毒中和抗体效价、特异性T细胞免疫,均显著高于国际上市的mRNA RSV对照疫苗。(jl/k)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-04 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10